NCT01399450 is a Phase 4 clinical trial of paliperidone in Schizophrenia, sponsored by Seoul National University Hospital.

Who is sponsoring NCT01399450?

NCT01399450 is sponsored by Seoul National University Hospital.

What drugs are being tested in NCT01399450?

Interventions in NCT01399450: paliperidone.

What condition does NCT01399450 study?

NCT01399450 studies Schizophrenia.

Is NCT01399450 still recruiting?

NCT01399450 is currently completed. Last updated 7 April 2019.

Last reviewed 2019-04-07 · How we verify

NCT01399450

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Paliperidone ER(Invega®) on Depressive Symptoms of Schizophrenia Patients: A 8-week Open-label Prospective, Non-comparative Study

Completed Phase 4 Last updated 7 April 2019

What this trial tests

Phase 4 trial testing paliperidone in Schizophrenia in 11 participants. Completed in 1 November 2016.

Timeline

1 August 2011

Primary endpoint
1 July 2016

1 November 2016

Quick facts

Lead sponsor	Seoul National University Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	1 August 2011
Primary completion	1 July 2016
Estimated completion	1 November 2016
Sites	2 locations across South Korea

Drugs / interventions tested

paliperidone — full drug profile →

Conditions studied

Schizophrenia — all drugs for Schizophrenia →

Sponsor

Seoul National University Hospital

Who can join

Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

MADRS(montgomery asberg depression rating scale)
Time frame: 8 weeks

Sponsor's own description

The purpose of this study is changing (improving), after initiating various doses of Paliperidone ER on schizophrenia patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of paliperidone

Trials testing the same drug.

NCT04478838 — "Extended" (Alternate Day) Antipsychotic Dosing · Phase 4 · recruiting
NCT03557931 — A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schiz · Phase 2 · completed

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Seoul National University Hospital trials

Trials by the same sponsor.

NCT07262944 — EOI Block in Otoplasty With Rib Cartilage Graft · NA · recruiting
NCT07464210 — Nemtabrutinib, Bortezomib, and Rituximab for WM · Phase 2 · not yet recruiting
NCT07550803 — Effect of Intraoperative Dexamethasone on Early Postoperative Sleep Quality in Patients Undergoing Nasal Surgery · NA · not yet recruiting
NCT07522138 — Home-based Self-exercise in Patients With Parkinson's Disease: A Feasibility Study · NA · not yet recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01399450 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Seoul National University Hospital
Last refreshed: 7 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01399450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing